In addition, aspirin induced acetylated COX-2 promotes the production of aspirin-triggered specialized proresolving mediators (AT-SPMs), including AT-lipoxin A4 and AT-resolvin D1, which can downregulate the expression of programmed cell death protein-1 (PD-1) in macrophages and CD8+T cells, and regulate tissue metabolism, reducing the production of several glycolysis intermediates, thereby improving anti-tumor immunity and reducing the incidence of drug resistance. The gene discussed is PDCD1; the disease is neoplasm.